Novo Nordisk presents new semaglutide cardiovascular data across multiple chronic diseases at the American College of Cardiology 74th Annual Scientific Sessions
Press Releases
March 17, 2025

Novo Nordisk presents new semaglutide cardiovascular data across multiple chronic diseases at the American College of Cardiology 74th Annual Scientific Sessions

Data spans various cardiometabolic conditions, including type 2 diabetes (T2D), obesity, peripheral arterial disease, and chronic kidney diseaseSOUL, a phase 3 trial, explored reduction of major adverse cardiovascular events (MACE)

bradford

The Bradford Era

Local & Social